Literature DB >> 33249728

Solute excretion, metabolism, and cardio-renoprotection via two distinct mechanisms revolutionize clinical outcomes.

Friedrich C Luft1.   

Abstract

Entities:  

Keywords:  SGLT2; cardiovascular disease; chronic kidney disease; finerenone; mineralocorticoid receptor

Year:  2020        PMID: 33249728     DOI: 10.1111/apha.13589

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


× No keyword cloud information.
  1 in total

1.  Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.

Authors:  Peter Kolkhof; Elke Hartmann; Alexius Freyberger; Mira Pavkovic; Ilka Mathar; Peter Sandner; Karoline Droebner; Amer Joseph; Jörg Hüser; Frank Eitner
Journal:  Am J Nephrol       Date:  2021-06-10       Impact factor: 3.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.